A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

NCT01621178 on ClinicalTrials.gov · last registry update 2019-09-19

Finished June 2016, after enrolling 577 people. Primary outcome, as filed: Change From Baseline in Hemoglobin A1c (HbA1c). dulaglutide is approved in the US, but not for chronic kidney disease — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P3
Drug: dulaglutide
Trulicity
Sponsor: Eli Lilly and Company
Sponsor type: Industry
Enrollment: 577
Started: 2012-07
Primary completion: 2016-06 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change From Baseline in Hemoglobin A1c (HbA1c)

Conditions studied

Type 2 Diabetes · Chronic Kidney Disease

Every field above is taken directly from the registry record. See all detected changes across the class, or the dulaglutide page for this molecule’s full trial and approval history.